Amati Global Investors

Manufacture 2030 is a digital platform focused on reducing resource consumption in global manufacturing by 2030. The company has developed M2030 bee, a cloud-based tool designed to help manufacturers enhance profitability by lowering operational costs and minimizing environmental impacts. This platform offers unique software that enables suppliers to measure, manage, and reduce greenhouse gas emissions. By providing essential data and support, Manufacture 2030 assists clients in achieving emissions reduction targets, ultimately leading to cost savings and a decrease in CO2 emissions throughout their manufacturing supply chains.

Flylogix specializes in the development of advanced unmanned aircraft designed for efficient over-horizon operations. The company provides a range of services, including maritime surveillance, oil spill response, airspace management, methane emissions monitoring, and unmanned logistics. By leveraging these technologies, Flylogix aims to deliver essential information from remote environments, thereby enabling businesses to enhance operational effectiveness while reducing carbon emissions and improving safety. The company's innovative approach offers cost-effective solutions for industries facing challenges in remote operations.

eleXsys Energy operates as a cleantech energy company. eleXsys Energy’s innovative technology unlocks the full potential of electricity networks, by providing services that enable a two way flow of electricity on grids

eleXsys Energy operates as a cleantech energy company. eleXsys Energy’s innovative technology unlocks the full potential of electricity networks, by providing services that enable a two way flow of electricity on grids

Amryt Pharma is a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics for patients with serious and life-threatening rare diseases. Founded in 2015 and based in London, the company offers several commercial products, including Myalept, which treats complications related to leptin deficiency in patients with generalized lipodystrophy, and Lojuxta, a medication for adults with homozygous familial hypercholesterolemia. Amryt Pharma is also advancing its research pipeline, including FILSUVEZ, aimed at treating the skin manifestations of epidermolysis bullosa, and AP103, a pre-clinical gene therapy for recessive dystrophic epidermolysis bullosa. The company markets its products across the Americas, Europe, and the Middle East, focusing on addressing high unmet medical needs in rare and orphan diseases.